These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 32153219

  • 21. A new recombinant factor VIII: from genetics to clinical use.
    Santagostino E.
    Drug Des Devel Ther; 2014; 8():2507-15. PubMed ID: 25548513
    [Abstract] [Full Text] [Related]

  • 22. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L, Peyvandi F, Chan AKC, Königs C, Zulfikar B, Yuan H, Simpson M, Álvarez Román MT, Carcao M, Staber JM, Dunn AL, Chou SC, d'Oiron R, Albisetti M, Demissie M, Santagostino E, Yarramaneni A, Wong N, Abad-Franch L, Gunawardena S, Fijnvandraat K, XTEND-Kids Trial Group.
    N Engl J Med; 2024 Jul 18; 391(3):235-246. PubMed ID: 39018533
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
    Drillaud N, Cussac V, Bertho PO, Horvais V, Beurrier P, Ternisien C, Rose J, Fouassier M, Babuty A, Trossaërt M.
    Transfusion; 2023 Dec 18; 63(12):2321-2327. PubMed ID: 37850587
    [Abstract] [Full Text] [Related]

  • 24. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A.
    Matsushita T, Mangles S.
    J Thromb Haemost; 2020 Sep 18; 18 Suppl 1(Suppl 1):26-33. PubMed ID: 32558236
    [Abstract] [Full Text] [Related]

  • 25. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
    Witarto BS, Visuddho V, Witarto AP, Sutanto H, Wiratama BS, Wungu CDK.
    F1000Res; 2021 Sep 18; 10():1049. PubMed ID: 35136579
    [Abstract] [Full Text] [Related]

  • 26. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
    Tosetto A, Neff A, Lentz SR, Santagostino E, Nemes L, Sathar J, Meijer K, Chowdary P, Shen C, Landorph A, Hampton K.
    Haemophilia; 2020 May 18; 26(3):450-458. PubMed ID: 32293786
    [Abstract] [Full Text] [Related]

  • 27. Half-life extended factor VIII for the treatment of hemophilia A.
    Tiede A.
    J Thromb Haemost; 2015 Jun 18; 13 Suppl 1():S176-9. PubMed ID: 26149020
    [Abstract] [Full Text] [Related]

  • 28. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA.
    Expert Rev Hematol; 2023 Jun 18; 16(8):567-573. PubMed ID: 37289594
    [Abstract] [Full Text] [Related]

  • 29. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S, Alamelu J, Ehrenforth S, Hanabusa H, Abdul Karim F, Kavakli K, Khodaie M, Staber J, Stasyshyn O, Yee DL, Rageliene L.
    Thromb Haemost; 2017 Aug 30; 117(9):1705-1713. PubMed ID: 28692108
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
    Wu R, Wang X, Zhao X, Cheng Y, Zhou Z, Sun J, Xu M, Li W, Xiao J, Yang F, Chen Y, Xu W, Huang J, Ma C, Gai W, Xie L, Yang R.
    Haemophilia; 2022 Nov 30; 28(6):e199-e208. PubMed ID: 35802040
    [Abstract] [Full Text] [Related]

  • 34. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
    Ezban M, Vad K, Kjalke M.
    Eur J Haematol; 2014 Nov 30; 93(5):369-76. PubMed ID: 24797664
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM, Corrales-Medina FF, Mannucci PM, Jiménez-Yuste V, Tarantino MD.
    Eur J Haematol; 2023 Nov 30; 111(5):757-767. PubMed ID: 37587687
    [Abstract] [Full Text] [Related]

  • 40. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
    Curry N, Albayrak C, Escobar M, Andre Holme P, Kearney S, Klamroth R, Misgav M, Négrier C, Wheeler A, Santagostino E, Shima M, Landorph A, Tønder SM, Lentz SR.
    Haemophilia; 2019 May 30; 25(3):373-381. PubMed ID: 30817066
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.